
Samer Al Hadidi/LinkedIn
Mar 18, 2025, 10:01
Samer Al Hadidi: Prior Exposure to Belantamab Mafodotin with Idecabtagene Vicluecel in Multiple Myeloma
Samer Al Hadidi, Assistant professor at UAMS Myeloma Center, posted on LinkedIn about recent paper he and colleagues co-authored, titled “Prior Exposure to Belantamab Mafodotin Influences Outcomes with Idecabtagene Vicluecel in Patients with Multiple Myeloma” published on American Society of Hematology Blood Advances.
Authors: Bhavesh Mohan Lal, Marah Alzubi, Jawad Alrawabdeh, John D. Shaughnessy, Jr, Fenghuang Zhan, Eric R. Siegel, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi
“Check out recent work published American Society of Hematology Blood Advances.
Prior Exposure to Belantamab, Mafodotin Influences Outcomes with Idecabtagene ,Vicluecel in Patients with Multiple Myeloma.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 18, 2025, 16:54
Mar 18, 2025, 16:25
Mar 18, 2025, 16:07
Mar 18, 2025, 14:56
Mar 18, 2025, 14:40
Mar 18, 2025, 13:16